Recombinant Human PSCA-Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01528P-100UG
Human PSCA on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human PSCA-Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01528P-100UG
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human PSCA-Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Leu12-Ser86. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | O43653 |
Target Symbol | PSCA |
Synonyms | PSCA; UNQ206; PRO232 |
Species | Human |
Expression System | HEK293 |
Tag | N-hFc |
Expression Range | Leu12-Ser86 |
Mol. Weight | The protein has a predicted MW of 34.3 kDa. Due to glycosylation, the protein migrates to 40-55 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human PSCA, hFc Tag at 2ug/ml (100ul/Well) on the plate. Dose response curve for Biotinylated Anti-PSCA Antibody, hFc Tag with the EC50 of 50.8ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Gastric cancer is a deadly malignancy and is a prognostically unfavorable entity with restricted therapeutic strategies available. Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein widely expressed in bladder, prostate, and pancreatic cancers. Existing studies have thoroughly recognized the availability of utilizing anti-PSCA CAR-T cells in the treatment of metastatic prostate cancer and non-small-cell lung cancer. |